Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today...
-
BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today...
-
BOSTON, Mass, March 31, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today...
-
BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive...
-
BOSTON, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. a biotechnology company developing next generation Antibody Drug Conjugates (“ADCs”) and Bispecific ADCs (“BsADCs), announced that...
-
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...